Epizyme Inc (NASDAQ:EPZM) – Analysts at Oppenheimer issued their Q2 2019 earnings estimates for shares of Epizyme in a note issued to investors on Wednesday, February 27th. Oppenheimer analyst L. Gershell forecasts that the biopharmaceutical company will post earnings of ($0.64) per share for the quarter. Oppenheimer has a “Outperform” rating and a $18.00 price target on the stock. Oppenheimer also issued estimates for Epizyme’s Q4 2019 earnings at ($0.95) EPS, FY2019 earnings at ($2.54) EPS, FY2020 earnings at ($0.82) EPS, FY2021 earnings at $0.29 EPS and FY2022 earnings at $1.49 EPS.
Get Epizyme alerts:Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.17.
Other research analysts also recently issued research reports about the company. BidaskClub downgraded Epizyme from a “strong-buy” rating to a “buy” rating in a report on Friday, February 22nd. Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $8.25 price target for the company in a report on Tuesday, December 4th. Cowen reissued a “buy” rating and issued a $18.00 price target on shares of Epizyme in a report on Tuesday, February 26th. ValuEngine raised Epizyme from a “sell” rating to a “hold” rating in a report on Saturday, December 15th. Finally, Roth Capital restated a “buy” rating on shares of Epizyme in a research note on Wednesday, February 27th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Epizyme currently has a consensus rating of “Buy” and an average price target of $18.40.
Shares of EPZM opened at $12.87 on Monday. The stock has a market capitalization of $938.14 million, a P/E ratio of -7.48 and a beta of 3.00. Epizyme has a one year low of $5.14 and a one year high of $21.40.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. NEA Management Company LLC raised its stake in Epizyme by 6.4% during the fourth quarter. NEA Management Company LLC now owns 6,877,518 shares of the biopharmaceutical company’s stock valued at $42,366,000 after buying an additional 416,667 shares in the last quarter. BlackRock Inc. raised its stake in Epizyme by 19.0% during the fourth quarter. BlackRock Inc. now owns 5,193,287 shares of the biopharmaceutical company’s stock valued at $31,990,000 after buying an additional 830,815 shares in the last quarter. Vanguard Group Inc raised its position in shares of Epizyme by 1.9% during the 3rd quarter. Vanguard Group Inc now owns 4,570,139 shares of the biopharmaceutical company’s stock worth $48,443,000 after purchasing an additional 84,726 shares during the period. Vanguard Group Inc. raised its position in shares of Epizyme by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 4,570,139 shares of the biopharmaceutical company’s stock worth $48,443,000 after purchasing an additional 84,726 shares during the period. Finally, Redmile Group LLC raised its position in shares of Epizyme by 11.2% during the 3rd quarter. Redmile Group LLC now owns 2,248,189 shares of the biopharmaceutical company’s stock worth $23,831,000 after purchasing an additional 226,800 shares during the period. Hedge funds and other institutional investors own 75.53% of the company’s stock.
About Epizyme
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Featured Story: How Do You Calculate Return on Equity (ROE)?
No comments:
Post a Comment